AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
1 June 2020 AbbVie, a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 is…
Certara Broadens and Increases Regulatory Strength with Two Executive Hires
21 May 2020 Certara®, the global leader in model-informed drug development and regulatory science announced the appointments of Terrance (Terry) Ocheltree, Ph.D., R.Ph. as vice president of regulatory strategy and chemistry, manufacturing and controls (CMC) and Lynne Georgopoulos,…
Human insulin enhanced with cone snail ‘blue print’
2 June 2020 Diabetes treatments could be improved following the development of a dramatically modified form of human insulin, called ‘Mini-Ins’, that successfully mimics the ultra-fast-acting properties of cone snail venom insulin. Mini-Ins has demonstrated significant promise…
Noxopharm: ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
1 June 2020 Highlights: NOX66 (Veyonda®) clinical data released to world-wide audience Anti-cancer responses (tumor size and pain responses) observed in approximately two-thirds of men with end-stage prostate cancer Abscopal responses in approximately one-quarter of men with end-stage…
Immutep Reports First Results from INSIGHT-004 Study
1 June 2020 First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCO Encouraging early activity signals in a variety of cancer indications Overall, 33% of patients showed…
Immutep Announces Improving Data from Phase II TACTI-002 Study
1 June 2020 First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC) Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR) Progression free survival (PFS) continues to improve in…
Immutep Receives A$3.6 Million R&D Tax Incentive from French Government
29 May 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €2,173,454 (~ A$3,630,000) research and development (R&D) tax incentive payment in cash…
Cloud-based bioinformatics platform fast-tracking genomic analysis
21 May 2020 Researchers at the University of Melbourne Centre for Cancer Research (UMCCR) have established a reliable, scalable and fast bioinformatics platform to analyse the genomic data of hundreds of cancer patients. This new cloud-computing based platform…
COVID-19 prevention trial opens for high risk healthcare workers
20 May 2020 The first gold standard Australian clinical trial to determine whether the drug hydroxychloroquine can prevent COVID-19 is now open. The study, called COVID SHIELD, will recruit frontline and allied health care professionals, aiming to reduce…
VivaZome and Cytiva enter into an agreement on downstream technology for exosome purification
21 May 2020 VivaZome Therapeutics Pty Ltd (“VivaZome”) and Cytiva, formerly part of GE Healthcare Life Sciences, have entered into an agreement where Cytiva’s range of purification technologies, including Fibro, will be applied to VivaZome’s selected exosome fractions,…
Israel becomes first Middle Eastern market for Sienna’s hTERT IVD
21 May 2020 Sienna Cancer Diagnostics Ltd is pleased to announce the appointment of Zotal Ltd (“Zotal”) as its exclusive distributor in Israel. The distribution agreement provides Zotal with the right to sell Sienna’s hTERT IVD to pathology…
MCRI launches landmark study into children’s COVID-19 immune responses with assistance from Rio Tinto
19 May 2020 The Murdoch Children’s Research Institute (MCRI) has launched its COVID Immune research program to investigate COVID-19 effects on children’s immune systems. The new program, an Australian first, has been made possible with support from Rio Tinto,…
